Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression Publisher Pubmed



Aryana K1 ; Manafifarid R2 ; Amini H3 ; Divband G3 ; Moghadam SZ4
Authors

Source: Clinical Nuclear Medicine Published:2022


Abstract

A 70-year-old man with mCRPC (metastatic castration-resistant prostate cancer) was referred for 68Ga-PSMA PET/CT for restaging and the possibility of targeted molecular radioligand therapy with 177Lu-PSMA. Numerous 68Ga-PSMA-avid skeletal metastases with low SUVs were noted. Because of low PSMA expression, a 68Ga-FAPI-46 PET/CT was performed to evaluate the eligibility for FAPI-based radioligand therapy. There were some discordant findings between 68Ga-PSMA and 68Ga-FAPI PET/CT scans regarding the detectability of lesions and SUVs. Our case signifies that 68Ga-FAPI theragnostic may have a potential role in the treatment of mCRPC patients with insignificant PSMA expression or in cases after the failure of 177Lu-PSMA therapy. © Wolters Kluwer Health, Inc. All rights reserved.
Related Docs
View other Related Docs
1. 68Ga-Fapi, a Twin Tracer for 18F-Fdg in the Era of Evolving Pet Imaging, Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative Approach (2023)
2. Bone Metastasis in Prostate Cancer: Bone Scan Versus Pet Imaging, Seminars in Nuclear Medicine (2024)
3. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends, Cancers (2021)
Experts (# of related papers)
View all Related Experts
Reyhaneh Manafi-Farid (6)
Babak Fallahi (5)
Other Related Docs
4. [68Ga]Ga-Psma-11 Pet/Ct and [18F]Fluorocholine Pet/Ct in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial, Molecular Imaging and Biology (2025)
5. Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-Psma Pet/Ct in Prostate Cancer: A Comparative Study, Journal of Clinical Medicine (2020)
6. Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy With [177Lu]Lu-Psma in Metastatic Castrate-Resistant Prostate Cancer: A Review, European Journal of Nuclear Medicine and Molecular Imaging (2021)
7. 99Mtc-Psma Spect/Ct Versus 68Ga-Psma Pet/Ct in the Evaluation of Metastatic Prostate Cancer, Clinical Nuclear Medicine (2021)
8. 68Ga-Psma Pet in Prostate Cancer: A Systematic Review And Meta-Analysis Of The Observer Agreement, European Journal of Nuclear Medicine and Molecular Imaging (2022)
9. An Update on the Role of Mpmri and 68Ga-Psma Pet Imaging in Primary and Recurrent Prostate Cancer, Clinical Genitourinary Cancer (2024)
10. Optimized Production, Quality Control, Biological Evaluation and Pet/Ct Imaging of 68Ga-Psma-617 in Breast Adenocarcinoma Model, Radiochimica Acta (2017)
11. Multiphasic 68Ga-Psma Pet/Ct in the Detection of Early Recurrence in Prostate Cancer Patients With a Psa Level of Less Than 1 Ng/Ml: A Prospective Study of 135 Patients, Journal of Nuclear Medicine (2020)
12. Machine Learning-Based Dose Prediction in [177Lu]Lu-Psma-617 Therapy by Integrating Biomarkers and Radiomic Features From [68Ga]Ga-Psma-11 Positron Emission Tomography/Computed Tomography, International Journal of Radiation Oncology Biology Physics (2025)
13. A Prospective Study on [68Ga]-Psma Pet/Ct Imaging in Newly Diagnosed Intermediate-And High-Risk Prostate Cancer, Asia Oceania Journal of Nuclear Medicine and Biology (2021)
14. Comparative Analysis of 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for Gross Tumor Volume Delineation in Radiation Therapy Planning of Prostate Cancer, Advances in Radiation Oncology (2025)
15. Factors Predicting the Early Biochemical Response to [177Lu]Lu-Psma Therapy in Patients With Metastatic Castration Resistant Prostate Cancer, Iranian Journal of Nuclear Medicine (2022)
16. The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma, Iranian Journal of Nuclear Medicine (2018)
17. Prognostic Significance of Baseline Clinical and [68Ga]Ga-Psma Pet Derived Parameters on Biochemical Response, Overall Survival, and Psa Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Undergoing [177Lu]Lu-Psma Therapy, Nuklearmedizin - NuclearMedicine (2024)
18. Optimal Time-Point for 68Ga-Psma-11 Pet/Ct Imaging in Assessment of Prostate Cancer: Feasibility of Sterile Cold-Kit Tracer Preparation?, European Journal of Nuclear Medicine and Molecular Imaging (2018)
19. Whole-Body Low-Dose Ct Can Be of Value in Prostate Cancer Decision-Making: A Retrospective Study on 601 Patients, Insights into Imaging (2023)
20. Personalized Dosimetry Assessment of [177Lu]Lu-Psma-617 Radioligand Therapy in the Management of Metastatic Castration-Resistant Prostate Cancer, International Journal of Radiation Biology (2024)